Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Assurance Cases Are Slowing Down Infusion Pump Submissions, Branch Chief Says

This article was originally published in The Gray Sheet

Executive Summary

The need for infusion pump manufacturers to prepare safety cases is slowing down 510(k) submissions for the products, said Richard Chapman, the head of CDRH's General Hospital Devices review branch.

You may also be interested in...



Final Guidance: Assurance Cases, But Not Always Clinicals, For Infusion Pumps

In response to a growing number of adverse events, FDA has asked infusion pump manufacturers to submit safety assurance cases to help understand the safety profile of their device when submitting a 510(K). But a final guidance appears to soften expectations that clinical studies always be performed to support clearance.

Financings In Brief

Fluidnet raises $25 million

Financings In Brief

Fluidnet raises $25 million

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030017

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel